Rezolute, Inc. (RZLT) operates in the biopharmaceutical industry, specifically focused on developing therapies for metabolic diseases related to chronic glucose imbalance. The company's main business activities involve the creation of treatments for congenital hyperinsulinism (HI) and diabetic macular edema (DME). Rezolute's operations span across various countries, with a significant presence in the United States.
Rezolute generates revenue through the development and commercialization of its primary products, RZ358 and RZ402. RZ3
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | VKTX | Viking Therapeutics, Inc. | - | - | - | - |
| 2 | BOLT | Bolt Biotherapeutics, Inc. | - | - | - | - |
| 3 | GERN | Geron Corp | - | - | - | 119.55 Mn |
| 4 | VTVT | vTv Therapeutics Inc. | - | - | - | - |
| 5 | DYAI | Dyadic International Inc | - | - | - | - |
| 6 | VIR | Vir Biotechnology, Inc. | - | - | - | - |
| 7 | NAMS | NewAmsterdam Pharma Co N.V. | - | - | - | 57.27 Mn |
| 8 | RLYB | Rallybio Corp | - | - | - | - |